- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03743415
Caregivers' and Cancer Survivors' Psychological Distress & Symptom Management
Improving Informal Caregivers' and Cancer Survivors' Psychological Distress, Symptom Management and Health Care Use
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Informal caregivers, typically family members or friends, provide more than half of the care needed for the 5.7 million cancer survivors (defined as individuals from diagnosis to end-of-life) in the United States, often with negative consequences to their health. Caregivers assist with the management of the survivor's symptoms such as fatigue, pain and insomnia, and others.Psychological distress (depression and anxiety) has been reported in at least 30% of survivors and their caregivers who are not always prepared for the task of symptom management. This research assists both the caregiver and survivor (the dyad in this study) to manage the survivor's cancer- and treatment-related symptoms and the distress of both members of the dyad in a sample of 298 survivors with elevated depression or anxiety and their 298 caregivers. Dyads will be recruited during the survivor's chemotherapy or targeted therapy for a solid tumor, a time when symptom burden and psychological distress are particularly high.
The investigators will use two evidence-based interventions extensively tested against active and passive controls in traditional randomized controlled trials (RCTs). While overall efficacy of these interventions has been established, individuals differ in their responses. When an intervention does not initially work, clinical logic is to either extend the timeframe or prescribe a different intervention. Yet, these alternatives are seldom tested and not evidence-based. The proposed project advances beyond a traditional RCT of testing fixed "one size fits all" interventions to the sequential multiple assignment randomized trial (SMART) design to build the evidence base for intervention sequencing that accounts for heterogeneity of responses.
The first intervention, a printed symptom management and survivorship handbook (Handbook) with strategies for self-management of symptoms common during chemotherapy will be given to both survivor and caregiver (the dyad). Handbook strategies, if successfully enacted, produce positive symptom responses for the survivor. However, psychological distress of the survivor or the caregiver may diminish the receipt and enactment of the Handbook strategies and also exacerbate the severity of other symptoms which, in turn, produces poor symptom responses. Research by this team has documented dyadic effects where survivors' psychosocial distress impacts that of the caregiver and vice versa. The survivor's and caregiver's distress exhibit similar trajectories. Therefore, the second intervention tested in sequencing is the 8-week telephone interpersonal counseling intervention (TIP-C) to manage psychological distress of the dyad.
The dyad (survivor-caregiver) will be randomly assigned to either: 1) Symptom Management and Survivorship Guideline (Handbook) alone or 2) Telephone Interpersonal Counseling (TIP-C) +Handbook for 8 weeks followed by continued Handbook alone for 4 weeks. During 12 weeks following initial randomization, all participants will receive weekly telephone contacts to assess symptoms, deliver the assigned intervention and assess its enactment and fidelity. After the initial 4 weeks in the Handbook alone group, the survivor's response to the intervention will be determined. If the survivor responds (defined as a reduced score on depression and/or anxiety), the dyad will continue with the Handbook alone for 8 more weeks. If the survivor is a non-responder (defined as no improvement or a worsening score for depression and/or anxiety), the dyad will be re-randomized to either continue with Handbook alone for 8 more weeks, or add 8 weeks of TIP-C. Outcomes will be assessed at baseline, weeks 13 and 17 for both members of the dyad.
The following specific aims will be tested.
- Determine if dyads in the TIP-C+Handbook as compared to the Handbook alone group created by the first randomization will have: a) lower depression, anxiety, and summed severity of 13 other symptoms at weeks 1-12, 13, and 17 (primary outcomes); b) lower use of healthcare services (hospitalizations, urgent care or emergency department [ED] visits) during 17 weeks (secondary outcomes); c) greater self-efficacy, social support, and lower caregiver burden during weeks 13 and 17 (potential mediators).
- Among non-responders to the Handbook alone after 4 weeks, determine if dyads in TIP-C+Handbook as compared to the Handbook alone group created by the second randomization will have better primary and secondary outcomes and potential mediators at weeks 5-12, 13, and 17.
- Test the interdependence in survivors' and caregivers' primary and secondary outcomes.
- Determine which characteristics of the dyad are associated with responses to the Handbook alone during weeks 1-4 and optimal outcomes for the dyad during weeks 1-12, 13 and 17 so as to determine tailoring variables for the decision rules of individualized sequencing of interventions in the future.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85721
- University of Arizona Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Inclusion criteria for the survivors are: 1) age 18 or older; 2) undergoing chemotherapy, hormonal therapy, or targeted therapy for a solid tumor cancer; 3) able to perform basic activities of daily living; 4) cognitively oriented to time, place, and person (determined by recruiter); 5) reporting severity of >2 on depression or >4 on anxiety using a 0-10 standardized scale; 6) able to speak and understand English or Spanish; 7) access to a telephone and 8) has a caregiver who can be in any relationship role (e.g., spouse, sibling, parent, friend) who can participate with them.
Inclusion criteria for the caregivers are: 1) age 18 or older; 2) able to speak and understand English or Spanish; 3) access to a telephone; 4) not currently receiving counseling and/or psychotherapy; and 5) not currently treated for cancer.
Exclusion Criteria:
- Exclusion criteria are: 1) diagnosis of a psychotic disorder in the health record; 2) nursing home resident; 3) bedridden; 4) currently receiving counseling and/or psychotherapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Handbook
The Symptom Management and Survivorship Handbook is a self-care management handbook with each symptom chapter presented in an identical format: what the symptom is, how people describe the symptom, the causes of the symptom, strategies for managing the symptom and resources.
The Handbook is available in English and Spanish.
Each weekly call will begin with the symptom assessment.
For each symptom rated at 4 or higher on a 0-10 scale of severity, the survivors will be referred for symptom self-management.
During weeks 2-12, Handbook use since the last call (intervention enactment) and symptoms will be assessed.
During weekly calls to caregivers, the caregivers will be notified of symptoms above threshold experienced by survivors and directed to the Handbook.
During weeks 2-12, Handbook use and symptoms are assessed, a summary of survivors' symptoms provided.
Calls will last about 10 minutes.
|
see arm/group descriptions
Other Names:
|
Experimental: TIP-C plus Handbook
Each survivor and caregiver will receive one 40-minute telephone call per week for 12 weeks.
The Telephone Interpersonal Counseling (TIP-C) intervention 8-week protocol is the same for both survivor and caregiver.
During weekly contacts, the counselors target social support behaviors using interpersonal communications techniques.
Counselors can personalize the counseling intervention for the specific needs or interests as expressed during sessions while still adhering to a structured protocol.
The final 4 weeks will be Handbook only.
|
see arm/group descriptions
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptom Severity Index- Comparison of Two Groups Created by First Randomization
Time Frame: Weeks 1-13 and week 17
|
Symptoms were measured using the modified General Symptom Distress Scale (GSDS), a brief instrument that measures 18 common symptoms fatigue, sleep difficulties, pain, headache, difficulty concentrating, lack of appetite, nausea, vomiting, constipation, diarrhea, numbness or tingling, skin rashes or sores, swelling, weakness, shortness of breath, cough, depression, and anxiety.
Respondents indicate severity of each symptom on the scale from 0=not present to 10=worst possible.
A summed symptom severity index for 16 symptoms other than depression and anxiety was computed by adding severities of 16 symptoms at each weekly contact (weeks 1-12) and week 13 interview for the immediate effects.
The summed symptom severity range is 0-160, a higher score reflects a worse outcome.
Week 17 value of the index was analyzed to determine the sustained effects.
|
Weeks 1-13 and week 17
|
Symptom Severity Index- Comparison of Two Groups Created by Second Randomization
Time Frame: Weeks 5-13 and week 17
|
Symptoms were measured using the modified General Symptom Distress Scale (GSDS), a brief instrument that measures 18 common symptoms fatigue, sleep difficulties, pain, headache, difficulty concentrating, lack of appetite, nausea, vomiting, constipation, diarrhea, numbness or tingling, skin rashes or sores, swelling, weakness, shortness of breath, cough, depression, and anxiety.
Respondents indicate severity of each symptom on the scale from 0=not present to 10=worst possible.
A summed symptom severity index for 16 symptoms other than depression and anxiety was computed by adding severities of 16 symptoms at each weekly contact (weeks 5-12) and week 13 interview for the immediate effects.
The summed symptom severity range is 0-160, a higher score reflects a worse outcome.
Week 17 value of the index was analyzed to determine the sustained effects.
|
Weeks 5-13 and week 17
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Depressive Symptoms- Comparison of Two Groups Created by First Randomization
Time Frame: Week 13 and week 17
|
Measured using Center for Epidemiological Studies- Depression (CES-D) 20-item scale.
Potential score range is 0-60.
Higher scores indicated worse outcome (higher depressive symptoms).
|
Week 13 and week 17
|
Depressive Symptoms- Comparison of Two Groups Created by Second Randomization
Time Frame: Week 13 and week 17
|
Measured using Center for Epidemiological Studies- Depression (CES-D) 20-item scale.
Potential score range is 0-60.
Higher scores indicated worse outcome (higher depressive symptoms).
|
Week 13 and week 17
|
Anxiety Symptoms- Comparison of Two Groups Created by First Randomization
Time Frame: Week 13 and week 17
|
Measured using Patient-Reported Outcomes Measurement Information System (PROMIS)-Anxiety 8a short form.
Each question is rated on a five-point scale from 1=Never to 5=Always.
The lowest possible raw score is 8; the highest possible raw score is 40.
Raw scores are converted into t-scores with potential range of 37.1 to 83.1.
Higher scores indicate greater anxiety.
The mean of the US general population is 50 with standard deviation 10.
Consensus-based but not data-based thresholds for scores in cancer populations are 50 for mildly symptomatic, 60 for moderately symptomatic, and 70 for severely symptomatic.
|
Week 13 and week 17
|
Anxiety Symptoms- Comparison of Two Groups Created by Second Randomization
Time Frame: Week 13 and week 17
|
Measured using Patient-Reported Outcomes Measurement Information System (PROMIS)-Anxiety 8a short form.
Each question is rated on a five-point scale from 1=Never to 5=Always.
The lowest possible raw score is 8; the highest possible raw score is 40.
Raw scores are converted into t-scores with potential range of 37.1 to 83.1.
Higher scores indicate greater anxiety.
The mean of the US general population is 50 with standard deviation 10.
Consensus-based but not data-based thresholds for scores in cancer populations are 50 for mildly symptomatic, 60 for moderately symptomatic, and 70 for severely symptomatic.
|
Week 13 and week 17
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Survivor and Caregiver Self-Efficacy
Time Frame: Baseline, week 13, 17
|
PROMIS Self-Efficacy for managing symptoms-sf4a.
Participants respond to each of the 4 items from 1 (I am not at all confident) to 5 (I am very confident).
Scores are summed and converted to T scores.
T scores are used in the analysis.
|
Baseline, week 13, 17
|
Change in Survivor and Caregiver Social Support
Time Frame: Baseline, weeks 13, 17
|
PROMIS Informational and Emotional Support-8 item short forms.
Participants respond to each item by telling how often it occurs from 1 (never) to 5 (always).
Scores are summed and converted to T scores.
T scores are used in the analysis.
|
Baseline, weeks 13, 17
|
Change in Caregiver Reactions
Time Frame: baseline, weeks 13, 17
|
Caregiver Reaction Assessment Tool is a 24 item scale to measure burdens of caregiving.
Participants respond to each item with 1 (strongly disagree) to 5 (strongly agree).
Subscale scores are summed with higher scores indicating higher positive or negative response to caregiving.
|
baseline, weeks 13, 17
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Terry Badger, PhD, University of Arizona
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 1804501501
- R01CA224282 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The investigators will share the findings and data with other researchers, the public, and key stakeholders based on the principles that NIH has articulated regarding the sharing of study results and resources. The University of Arizona agrees that data sharing is essential for expedited translation of research results into knowledge, products, and procedures to improve health.
Sharing of study results Manuscript based on results from the proposed study will be published in peer-reviewed journals. The investigators will select "open access" options for these manuscripts whenever possible.
Data Sharing Data from this study will be available to other researchers under the following conditions: 1) appropriate human subjects protection is in place; 2) data have been de-identified; and 3) study investigators have publicly presented and published key findings. Data and safety monitoring plan is described under Human Subjects.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on Handbook
-
Penn State UniversityCompleted
-
University of Campinas, BrazilCompleted
-
Boston Children's HospitalPfizerCompletedDermatitis, AtopicUnited States
-
Guohua ZengUnknown
-
Massachusetts General HospitalCompletedHead and Neck CancerUnited States
-
National Taiwan University HospitalActive, not recruiting
-
Boston Children's HospitalMcMaster UniversityCompletedEvaluating the Effectiveness of a Handbook for Parents of Children Newly Diagnosed With Food AllergyHypersensitivity, FoodUnited States
-
University of Dublin, Trinity CollegeTallaght University Hospital; St. James Hospital; Waterford University HospitalRecruitingInflammatory ArthritisIreland
-
Universidad de GranadaEnrolling by invitationBreast NeoplasmsSpain
-
Washington State UniversityUnknownSubstance Abuse | Risk Reduction | RIsky Sexual BehaviorUnited States